Published Guidance, NICE advice and quality standards

Skip to filters Skip to results

Showing 651 to 660 of 761

Sort by

Type: GuidanceRemove Type: Guidance filter
Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism	TA261	25 July 2012	25 July 2012
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2	TA257	27 June 2012	27 June 2012
Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer	TA258	27 June 2012	27 June 2012
Botulinum toxin type A for the prevention of headaches in adults with chronic migraine	TA260	27 June 2012	27 June 2012
Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis	TA254	25 April 2012	25 April 2012
Pharmalgen for the treatment of bee and wasp venom allergy	TA246	22 February 2012	22 February 2012
Tocilizumab for the treatment of rheumatoid arthritis	TA247	22 February 2012	22 February 2012
Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy	TA242	25 January 2012	25 January 2012
Rituximab for the first-line treatment of stage III-IV follicular lymphoma	TA243	25 January 2012	25 January 2012
Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults	TA245	25 January 2012	25 January 2012

Results per page

10
25
50
All